Therapeutic Methods And Pharmaceutical Compositions For Treating Warts With Tellurium Compounds

Abstract

A novel method for treating skin and mucosal membrane ailments caused by human papilloma viruses, which utilizes tellurium-containing compounds, is disclosed. Also disclosed are pharmaceutical compositions containing tellurium-containing compounds for treating such ailments.

We claim: 
     
         1 . A pharmaceutical composition identified for use in the treatment of a skin or mucosal membrane ailment caused by a human papilloma virus (HPV), comprising at least one tellurium-containing compound and a pharmaceutically acceptable carrier. 
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein said at least one tellurium-containing compound is selected from the group consisting of tellurium dioxide (TeO 2 ), a complex of TeO 2 , a compound having general Formula 1: 
       
         
           
           
               
               
           
         
         compound having general Formula II: 
       
       
         
           
           
               
               
           
         
         a compound having general Formula III: 
       
       
         
           
           
               
               
           
         
         and 
         a compound having general Formula IV: 
       
       
         
           
           
               
               
           
         
         wherein:
 each of t, u and v is independently 0 or 1; 
 each of m and n is independently an integer from 0 to 3; 
 Y is selected from the group consisting of ammonium, phsophonium, potassium, sodium and lithium; and 
 each of R 1 -R 22  is independently selected from the group consisting of hydrogen, hydroxyalkyl, hydroxy, thiohydroxy, alkyl, alkenyl, alkynyl, alkoxy, thioalkoxy, halogen, haloalkyl, carboxy, carbonyl, alkylcarbonylalkyl, alkoxy, carboxyalkyl, acyl, amido, cyano, N-monoalkylamidoalkyl, N,N-dialkylamidoalkyl, cyanoalkyl, alkoxyalkyl, carbamyl, cycloalkyl, heteroalicyclic, sulfonyl, sulfanyl, amine, aryl, heteroaryl, phosphate, phosphonate and sulfoneamido. 
 
       
     
     
         3 . The pharmaceutical composition of  claim 2 , wherein said tellurium-containing compound is selected from the group consisting of a compound having said general Formula I and a compound having said general Formula II. 
     
     
         4 . The pharmaceutical composition of  claim 3 , wherein t, u and v are each 0. 
     
     
         5 . The pharmaceutical composition of  claim 3 , wherein X is halogen. 
     
     
         6 . The pharmaceutical composition of  claim 5 , wherein Y is ammonium. 
     
     
         7 . The pharmaceutical composition of  claim 2 , wherein said tellurium-containing compound has said general Formula III. 
     
     
         8 . The pharmaceutical composition of  claim 2 , wherein said tellurium-containing compound has said general Formula IV. 
     
     
         9 . The pharmaceutical composition of  claim 2 , wherein said complex of TeO2 is TeO2.HOCH2CH2OH.NH4Cl. 
     
     
         10 . The pharmaceutical composition of  claim 1 , being formulated for systemic administration. 
     
     
         11 . The pharmaceutical composition of  claim 1 , being formulated for topical administration. 
     
     
         12 . The pharmaceutical composition of  claim 11 , wherein a concentration of said at least one tellurium-containing compound ranges from about 0.01 weight percent to about 50 weight percents of the total weight of the composition. 
     
     
         13 . The pharmaceutical composition of  claim 12 , wherein a concentration of said at least one tellurium-containing compound ranges from about 5 weight percents to about 25 weight percents of the total weight of the composition. 
     
     
         14 . The pharmaceutical composition of  claim 1 , further comprising at least one additional active agent. 
     
     
         15 . The pharmaceutical composition of  claim 14 , wherein said additional active agent is selected from the group consisting of an antibiotic agent, an antimicrobial agent, an anti-acne agent, an antibacterial agent, an antifungal agent, an antiviral agent, a steroidal anti-inflammatory agent, a non-steroidal anti-inflammatory agent, an anesthetic agent, an antipruriginous agent, an antiprotozoal agent, an anti-oxidant, a chemotherapeutic agent, an antidepressant, an antihistamine, a vitamin, a hormone, a keratolytic agent and an antidandruff agent. 
     
     
         16 . The pharmaceutical composition of  claim 1 , further comprising at least one additional active agent being capable of treating said skin or mucosal membrane ailment caused by HPV. 
     
     
         17 . The pharmaceutical composition of  claim 1 , having a pH that ranges from 4 to 7. 
     
     
         18 . The pharmaceutical composition of  claim 17 , having a pH that ranges from 4 to 6. 
     
     
         19 . The pharmaceutical composition of  claim 1 , wherein said skin or mucosal membrane ailment is selected from the group consisting of verruca vulgaris, plantar warts, palmar warts, periungal warts, planar warts, mosaic warts, genital warts, venereal warts (condylomata acuminata), butcher's warts, malignant epidermodyspasia verruciformis, advanced intraepithelial dysplasia, cervical cancer, mepidermodysplasia verruciformis, cutnaeous warts in immunosuppressed patients, laryngeal papillomas and oral papilloma. 
     
     
         20 . The pharmaceutical composition of  claim 1 , being packaged in a packaging material and identified in print, in or on said packaging material, for use in the treatment of said skin or mucosal membrane ailment.